Johnson & Johnson für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 853260 / ISIN: US4781601046

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Orderbuch	Analysen
Historisch

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Orderbuch
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Johnson & Johnson

17.11.25		J&J's Tremfya Shows Strong 48-Week Results In Phase 3b Psoriatic Arthritis Study (RTTNews)
17.11.25		Johnson & Johnson To Acquire Halda Therapeutics In $3.05 Bln All-cash Deal (RTTNews)
17.11.25		New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis (EN, Johnson & Johnson)
17.11.25		Johnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics (EN, Johnson & Johnson)
14.11.25		Bristol Myers Squibb, J&J Discontinue Phase 3 Librexia ACS Study Of Milvexian After Interim Review (RTTNews)
07.11.25		Halozyme, JNJ Win FDA Approval For DARZALEX Faspro In High-Risk Smoldering Multiple Myeloma (RTTNews)
06.11.25		DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma (EN, Johnson & Johnson)
06.11.25		FDA Approves J&J' Caplyta As Add-On Therapy For Major Depressive Disorder In Adults (RTTNews)
06.11.25		FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder (EN, Johnson & Johnson)
04.11.25		Johnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research (EN, Johnson & Johnson)
04.11.25		Johnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025 (EN, Johnson & Johnson)
03.11.25		Johnson & Johnson Confirms Durability of IVL in Complex, Below-the-Knee Anatomy in Late-Breaking Presentation at VIVA 2025 (EN, Johnson & Johnson)
03.11.25		Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS (EN, Johnson & Johnson)
31.10.25		Johnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis (EN, Johnson & Johnson)
29.10.25		Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting (EN, Johnson & Johnson)
28.10.25		Johnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare (EN, Johnson & Johnson)
27.10.25		JNJ Studies Show Positive Impact Of TREMFYA In Crohn's Disease Patients (RTTNews)
27.10.25		Johnson & Johnson Reports Positive Phase 2b Results For Icotrokinra In Ulcerative Colitis (RTTNews)
27.10.25		Johnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare (EN, Johnson & Johnson)
27.10.25		New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile (EN, Johnson & Johnson)
27.10.25		TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years (EN, Johnson & Johnson)
27.10.25		Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis (EN, Johnson & Johnson)
25.10.25		Johnson & Johnson's Nipocalimab Shows Promise In Reducing Sjögren's Disease Severity (RTTNews)
25.10.25		Published in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies (EN, Johnson & Johnson)
24.10.25		Johnson & Johnson Reports Strong 52-Week Data For Oral Psoriasis Drug Icotrokinra (RTTNews)
24.10.25		Johnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025 (EN, Johnson & Johnson)
24.10.25		Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis (EN, Johnson & Johnson)
20.10.25		Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy (EN, Johnson & Johnson)
19.10.25		Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer (EN, Johnson & Johnson)
16.10.25		TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care (EN, Johnson & Johnson)
15.10.25		Johnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types (EN, Johnson & Johnson)
14.10.25		Johnson & Johnson Backs FY25 Earnings View, Lifts Sales Forecast After Q3 Beats Market - Update (RTTNews)
14.10.25		Johnson & Johnson Plans To Separate Orthopaedics Unit; Names Namal Nawana Worldwide President (RTTNews)
14.10.25		Johnson & Johnson Q3 Profit Increases, Beats Estimates (RTTNews)
14.10.25		Johnson & Johnson announces intent to separate its Orthopaedics business (EN, Johnson & Johnson)
14.10.25		Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook (EN, Johnson & Johnson)
13.10.25		Johnson & Johnson Launches INHANCE INTACT™: A Total Shoulder Replacement System Designed for Tissue-Sparing Surgery Providing Day-One Post-Op Mobility (EN, Johnson & Johnson)
10.10.25		Johnson & Johnson Initiates CORE-VA Registry to Advance Ventricular Arrhythmia Ablation Care* (EN, Johnson & Johnson)
10.10.25		Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress (EN, Johnson & Johnson)
08.10.25		U.S. FDA approves SIMPONI® (golimumab) for the treatment of pediatric ulcerative colitis (EN, Johnson & Johnson)
07.10.25		Johnson & Johnson Hit With $966 Mln Verdict In Talc Lawsuit (RTTNews)
07.10.25		Johnson & Johnson Reports Positive Phase 2b Results For Icotrokinra In Ulcerative Colitis (RTTNews)
07.10.25		Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill (EN, Johnson & Johnson)
07.10.25		TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis (EN, Johnson & Johnson)
07.10.25		Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses (EN, Johnson & Johnson)
29.09.25		U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor (EN, Johnson & Johnson)
29.09.25		J&J: FDA Approves TREMFYA For Treatment Of Pediatric Plaque Psoriasis And Active Psoriatic Arthritis (RTTNews)
24.09.25		The Johnson & Johnson Foundation Announces $5 Million Expanded Investment in Africa Frontline First Catalytic Fund to Strengthen the Community Health Workforce (EN, Johnson & Johnson)
22.09.25		Johnson & Johnson’s investigational seltorexant shows numerically higher response in patients with depression with insomnia symptoms, with fewer side effects compared to quetiapine XR (EN, Johnson & Johnson)
20.09.25		Johnson & Johnson's TREMFYA Gains FDA Nod For SC Induction In Ulcerative Colitis (RTTNews)

1 | Weiter

Newssuche

Johnson & Johnson Peer Group Nachrichten

06:45		Frankreich: Nestlé setzt sich im Perrier-Streit zunächst durch
18.11.25		Roche-Aktie deutlich höher: Roche erzielt Studienerfolge mit neuem MS-Mittel Fenebrutinib
18.11.25		Dow Jones 30 Industrial-Papier Merck-Aktie: So viel Gewinn hätte ein Investment in Merck von vor 10 Jahren eingebracht
18.11.25		S&P 500-Titel Pfizer-Aktie: So viel hätte eine Investition in Pfizer von vor 10 Jahren gekostet
18.11.25		EURO STOXX 50-Titel Sanofi-Aktie: So viel Gewinn hätte ein Investment in Sanofi von vor 3 Jahren eingefahren
18.11.25		DAX 40-Wert Fresenius SE-Aktie: So viel hätten Anleger an einem Fresenius SE-Investment von vor 5 Jahren verdient
17.11.25		Formycon-Aktie zieht an: Formycon arbeitet an Biosimilar für Dupixent von Sanofi
17.11.25		DAX 40-Titel Beiersdorf-Aktie: So viel Verlust hätte ein Beiersdorf-Investment von vor 5 Jahren eingefahren

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	19.11.2025 07:34
Kaufwert:	EUR
	Hinzufügen Speichern

Johnson & Johnson Aktie

WKN: 853260 / ISIN: US4781601046

Nachrichten zu Johnson & Johnson

Newssuche

Johnson & Johnson Peer Group Nachrichten

Meistgelesene Nachrichten